### Table A3: GRADE summary for the primary outcomes

|  |  |  |
| --- | --- | --- |
| **Intervention** | **Change in MMDs** | **TEAEs** |
| **Compared with placebo** |  |  |
| Eptinezumab | High | High |
| Erenumab | High | High |
| Fremanezumab | High | High |
| Galcanezumab | High | High |
| **Compared with eptinezumab** |  |  |
| Erenumab | Low†§ | Moderate§ |
| Fremanezumab | Moderate | Moderate§ |
| Galcanezumab | Moderate§ | Moderate§ |
| **Compared with erenumab** |  |  |
| Fremanezumab | Moderate§ | Moderate§ |
| Galcanezumab | Moderate§ | Moderate§ |
| **Compared with fremanezumab** |  |  |
| Galcanezumab | Moderate§ | Moderate§ |

MMDs: monthly migraine days; TEAEs: treatment-emerging adverse events

† Rated down for imprecision.

§ Rated down for indirectness